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With the growing understanding of complex diseases, the focus of drug discovery has shifted away from the well-
accepted “one target, one drug” model, to a new “multi-target, multi-drug” model, aimed at systemically modulating
multiple targets. Identification of the interaction between drugs and target proteins plays an important role in genomic
drug discovery, in order to discover new drugs or novel targets for existing drugs. Due to the laborious and costly
experimental process of drug-target interaction prediction, in silico prediction could be an efficient way of providing
useful information in supporting experimental interaction data. An important notion that has emerged in post-
genomic drug discovery is that the large-scale integration of genomic, proteomic, signaling and metabolomic data can
allow us to construct complex networks of the cell that would provide us with a new framework for understanding the
molecular basis of physiological or pathophysiological states. An emerging paradigm of polypharmacology in the post-
genomic era is that drug, target and disease spaces can be correlated to study the effect of drugs on different spaces
and their interrelationships can be exploited for designing drugs or cocktails which can effectively target one or more
disease states. The future goal, therefore, is to create a computational platform that integrates genome-scale metabolic
pathway, protein–protein interaction networks, gene transcriptional analysis in order to build a comprehensive network
for multi-target multi-drug discovery.Purpose
Identification of the interaction between drugs and target
proteins plays an important role in genomic drug discov-
ery, in order to discover new drugs or novel targets for
existing drugs. Due to the laborious and costly experimen-
tal process of drug-target interaction prediction, in silico
prediction could be an efficient way of providing useful in-
formation in supporting experimental interaction data.
Since, a small number of experimental drug-target inter-
action data has been reported in current and publicly
available databases, this has motivated many researchers
to develop high performance computational approaches
capable of detecting new pairs of drug-target interaction
efficiently.
Drug-target network (DTN) is a bipartite graph in which
every link connects a drug to a protein if the protein is a
known target of the drug (Yildirim et al. 2007). To gener-
ate a DT network, all FDA-approved drugs and their
known targets are used and the information about drug-* Correspondence: amasoudin@ibb.ut.ac.ir
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reproduction in any medium, provided the origtarget interactions could be extracted from known data-
bases, including KEGG DRUG (Goto et al. 2002), Drug-
Bank (Wishart et al. 2008) and others.
Yildirim et al. released some significant features related
to the network topology of the DT network by applying
network analysis to drugs and target proteins. Based on
their findings, the membrane proteins are mostly targets
of FDA-approved drugs which belong to the same Ana-
tomical Therapeutic Chemical (ATC) class that naturally
target the same proteins. To investigate the relationships
between approved drugs, they integrated all available DT
interaction data along with genetic-disease associations,
gene expression and protein-protein interaction data.
Related works
A variety of computational methods have been proposed
to analyze and detect new protein-ligand interactions.
To the best of our knowledge, traditional computational
approaches can be categorized in three classes, namely
ligand-based, target-based, and text-mining methods. The
Ligand-based approach like QSAR (Quantitative Structure
Activity Relationship) uses machine learning methods to
predict protein-ligand interaction by comparing a new. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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et al. 2002; Byvatov et al. 2003). When the number of
known ligands for a target protein of interest is insufficient,
this approach couldn’t be effective in the prediction of
interaction. Target-based approach or docking simulation
rely on the 3D structure of proteins to predict protein-
ligand interaction and it can’t be applied to proteins with
unknown 3D structure (Cheng et al. 2007; Donald 2011;
Morris et al. 2009). This limitation is very serious for
membrane proteins such as Ion channels and G-Protein
Coupled Receptors (GPCRs) due to the complexity of de-
termining 3D structures of most of these proteins. Another
approach involves text mining methods which are based
on keyword searching in literatures but the redundancy in
the name of the gene/compound in the literatures is a
major concern in this approach (Zhu et al. 2005).
To predict the drug-target interaction, another inter-
esting approach was proposed by Campillos et al. based
on the side-effect similarities between known drugs
(Campillos et al. 2008). Nevertheless, this approach has
been verified by in vitro experiments in some cases, it
can only apply to the marketed drugs with known side
effects and to the interaction between new drugs cannot
be predicted by this approach. Recently, the importance
of chemogenomic approaches in the domain of protein-
ligand interaction prediction has grown fast (Dobson
2004; Kanehisa et al. 2006; Stockwell 2000). These
methods integrate both genomic spaces of target pro-
teins, and chemical space of compounds, to predict new
drug-target pairs. A unified space, namely “pharmaco-
logical space”, could be created by the integration of
drug chemical structures, protein sequences and drug-
target network topology to infer unknown drug-target
interactions. The underlying idea is that drugs with simi-
lar chemical structures are likely to interact with similar
proteins, and the prediction could be performed by
extracting different features for drugs and proteins to
define the similarity between two compounds or two
proteins.
Based on this concept, a variety of statistical and learn-
ing methods have been developed to predict drug-target
interaction (Bleakley and Yamanishi 2009; Chen et al.
2012; Cheng et al. 2012; Mei et al. 2012; van Laarhoven
et al. 2011; Xia et al. 2010; Xie et al. 2012; Yamanishi et al.
2008). Although promising results have been gained by
using these methods, most of them can only predict
whether a drug interacts with a target protein, but reveal
no further information about how this interaction oc-
curred. Unlike these methods, Wang et al. have proposed
a method based on the restricted Boltzmann machine to
predict different types of interaction between drugs and
targets (Wang and Zeng 2013). This state-of-the-art tech-
nique involves research that takes into account the drug-
target network in their analyses. “Network pharmacology”or “Systems pharmacology” is therefore a possible next
paradigm in drug discovery which is generated by the
advances in these areas (Hopkins 2007, 2008).Discussion
The improvements in drug discovery for complex diseases
could be achieved by studying drug action through the
network biology. With the growing understanding of com-
plex diseases, the focus of drug discovery has shifted away
from the well-accepted “one target, one drug” model, to a
new “multi-target, multi-drug” model, aimed at systemic-
ally modulating multiple targets. In this context, polyphar-
macology has emerged as a new paradigm to overcome
the recent decline in productivity of pharmaceutical re-
search (Wermuth 2004). Drug designers traditionally con-
sider the polypharamacology as an unwanted property
that must be removed or reduced to produce drugs that
interact with a single target. But in the modern pharma-
ceutical industry, the hitherto strategy of, “one drug for
one target for one disease”, has been considered respon-
sible for the more-funding-less-drug problem. Recent re-
search has shown that effective treatments of complex
diseases are not possible by interventions at single nodes.
To modify phenotypes, it is required that multiple pro-
teins be modulated simultaneously. Thus, drugs which act
on two or more targets of interest should be more impres-
sive than single-target ones. Assessing the role of poly-
pharmacology in drug action through drug-target network
analysis may provide insights into which drugs are more
efficacious in the treatment of complex diseases.
The integration of drug-target network with the human
disease network revealed that drug targets are often in-
volved in multiple diseases. Another analysis of the OMIM
database of genetic associations manifest that most disease
shares the genetic origins with others. According to these
findings, drug repositioning has been growing in import-
ance in the last few years for the application of known
drugs in new directions. In addition, the mapping of drug
targets on to the human protein interaction network re-
veals that the drug targets tend to be highly connected.
Thus, the integration of drug-target network with other
biological networks can help with drug discovery in pro-
ducing drugs with more efficacies and less toxicity. Recent
research also indicates that besides primary network pa-
rameters, more complex network metrics such as motifs
and clusters may also be appropriate parameters for con-
trolling the metabolic systems. Moreover, for metabolic
networks, enzyme-centric networks could be more reliable
in the context of controllability, although little attention
has been paid to such networks in systems controllability.
The outcomes of metabolic network controllability could
create insights into the discovery of novel drug targets
(Asgari et al. 2013).
Figure 1 Polypharmacology in the post-genomic era using pharmacological space.
Masoudi-Nejad et al. In Silico Pharmacology 2013, 1:17 Page 3 of 4
http://www.in-silico-pharmacology.com/content/1/1/17Drug discovery also can be influenced by the exploit-
ation of “omics” data. Due to the advances in genomics,
transcriptomics, proteomics and metabolomics, large
amounts of data have been provided on drug-target in-
teractions. To speed up the drug development process,
the information flow must be analyzed by more effective
tools in the early stages of drug discovery pipeline. The
emerging field of “systems pharmacology”, which relies
on “omics” technologies, can explain both therapeutic
and adverse effects of drugs through analyses at multiple
scales of biological networks (Figure 1).Conclusions
An important notion that has emerged in post-genomic
drug discovery is that the large-scale integration of gen-
omic, proteomic, signaling and metabolomic data can
allow us to construct complex networks of the cell that
would provide us with a new framework for understand-
ing the molecular basis of physiological or pathophysio-
logical states. Such an integrated view has important
implications in improving our understanding of the dis-
ease phenotypes by viewing them as perturbations in a
complex system rather than as effects on a selective set
of proteins. Using such a framework, network based
drug discovery aims to harness this knowledge to inves-
tigate and understand the impact of interventions, such
as candidate drugs, on the molecular networks thatdefine different states and therefore can significantly
complement the existing drug discovery pipelines.
An emerging paradigm of polypharmacology in the post-
genomic era is that drug, target and disease spaces can be
correlated to study the effect of drugs on different spaces
and their interrelationships can be exploited for designing
drugs or cocktails which can effectively target one or more
disease states (Janga and Tzakos 2009). This understanding
could lead to the introduction of new multidrug treat-
ments, side-effect prediction and the identification of new
drug targets. The future goal, therefore, is to create a com-
putational platform that integrates genome-scale metabolic
pathway, protein–protein interaction networks, gene tran-
scriptional analysis in order to build a comprehensive net-
work for multi-target multi-drug discovery (Figure 1).Competing interests
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